Helus Pharma Announces Positive Topline Results from Phase 3 APPROACH Study evaluating HLP003 as Adjunctive Treatment in Major Depressive Disorder

详细摘要
HLP003 achieved statistically significant and clinically meaningful results in the primary and key secondary endpoints starting as early as Day 2 and maintained at all time points…
HLP003 achieved statistically significant and clinically meaningful results in the primary and key secondary endpoints starting as early as Day 2 and maintained at all time points
-7.6 point placebo-adjusted change from baseline at Week 6 for the primary endpoint on the Montgomery-Asberg Depression Rating Scale (“MADRS”) (p< 0.0001)
Durable effect maintained through Week 12 (key secondary endpoint) with a -7.0 point placebo-adjusted change from baseline on the MADRS (p< 0.0001)
Robust and statistically significant response and remission rates starting as early as Day 2 and maintained at all time points
This news release constitutes a “designated news release” for the purpose of the Company’s prospectus supplement dated December 30, 2025, to its short form base shelf prospectus dated September 17, 2025, as amended on December 19, 2025.
NEW YORK and TORONTO,, Nov. 16, 2026 (GLOBE NEWSWIRE) — Helus Pharma Inc. (Nasdaq: HELP) (Cboe CA: HELP) (“Helus Pharma” or the “Company”), a clinical-stage pharmaceutical company committed to improving the treatment landscape in mental health conditions through the development and commercialization of novel serotonergic agonists (“NSAs”), today announced positive topline results from APPROACH, its Phase 3 pivotal study evaluating HLP003 (deuterated psilocin), as an adjunctive treatment for adults with major depressive disorder (“MDD”).
HLP003 achieved statistically significant and clinically meaningful results in the primary, key secondary and other secondary endpoints starting as early as Day 2 and these were maintained at all time points.
At the primary endpoint of 6 weeks, the least squares (“LS”) mean reduction from baseline in the MADRS total score for HLP003 was 19.5 points versus 11.9 points for placebo (LS mean difference = -7.6 points, p
The rapid onset of action with HLP003 was demonstrated with statistically significant LS mean MADRS reductions as early as Day 2 of 16.1 points versus 11.0 points for placebo (LS mean difference =…
文章开头,摘自Toronto Star。如需阅读全文,请前往媒体网站。
MarketNews 仅展示媒体发布的标题和摘要,全文请在出版方网站阅读。 (www.thestar.com)


